(Q42244740)

19 October 2017

JSH Guidelines for the Management of Hepatitis B Virus Infection (English)

1 reference

19 October 2017

1 reference

1 reference

Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology

series ordinal

1

1 reference

19 October 2017

1 January 2014

1 reference

19 October 2017

1 reference

19 October 2017

44 Suppl S1

1 reference

19 October 2017

1-58

1 reference

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

19 October 2017

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B virus infection--natural history and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Natural history of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Updated definitions of healthy ranges for serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Family history influences the early onset of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Measurement of liver elasticity with acoustic radiation force impulse (ARFI) technology: an alternative noninvasive method for staging liver fibrosis in viral hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatocellular carcinoma: the point of view of the hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Classifying hepatitis B virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

T1764G1766 core promoter double mutants are restricted to Hepatitis B virus strains with an A1757 and are common in genotype D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

A personalized approach to optimize hepatitis B treatment in treatment-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Management of chronic hepatitis B: status and challenges beyond treatment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

The interferon response circuit: induction and suppression by pathogenic viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

21 January 2018

Viruses and interferons

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

How cells respond to interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Clinical Pharmacokinetics of Interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Administration of interferon at night may increase its therapeutic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Tailored regimen of interferon alpha for HBeAg-positive chronic hepatitis B: a prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B genotypes and the response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

The neuroimmunology of stress and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Predicting relapse after cessation of Lamivudine monotherapy for chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Clinical and virological effects of long-term (over 5 years) lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Clinical course of patients with chronic hepatitis B with viral breakthrough during long-term lamivudine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Virologic response and resistance to adefovir in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Fanconi's Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: phase II clinical study in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B virus resistance to nucleos(t)ide analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Successful treatment of an entecavir-resistant hepatitis B virus variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

The clinical significance of persistently normal ALT in chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

DNA-dependent activator of interferon-regulatory factors inhibits hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

'e' antigen defective hepatitis B virus and course of chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

The study of efficacy of lamivudine in patients with severe acute hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Clinical features of hepatitis B virus genotype A in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

The HBV drug entecavir - effects on HIV-1 replication and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Case-control study for the identification of virological factors associated with fulminant hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Indications for therapy in hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Lamivudine treatment improves the prognosis of fulminant hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Liver grafts from anti-hepatitis B core positive donors: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

The use of lamivudine for patients with acute hepatitis B (a series of cases).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Entecavir to treat severe acute hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Attempted treatment of fulminant viral hepatitis with human fibroblast interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

HBV reactivation after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B virus reactivation and alemtuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy : case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Prevalence of hepatitis B virus infection in Japanese patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Predominance of genotype A HBV in an HBV-HIV-1 dually positive population compared with an HIV-1-negative counterpart in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance and Clinical Safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12269

21 January 2018

Identifiers

DOI

10.1111/HEPR.12269

1 reference

19 October 2017

1 reference

PubMed ID

24397839